EMULSIFIED COMPOSITION FOR DILUTION AND CANCER VACCINE COMPOSITION
Provided is an emulsified composition for diluting a cancer antigen peptide or a dimer thereof. Also provided is a novel cancer vaccine composition or specific CTL inducer that efficiently induces CTL irrespective of the type of cancer antigen peptide when mixing the emulsified composition for dilution and a water phase comprising a cancer antigen peptide or a dimer thereof. The present invention relates to an emulsified composition for diluting a cancer antigen peptide or a dimer thereof, comprising a particular ester, a particular surfactant, a particular emulsifier, and a water phase. The present invention also relates to a cancer vaccine composition or specific CTL inducer obtained by freshly diluting and mixing a water phase comprising a cancer antigen peptide or a dimer thereof with the emulsified composition for dilution.
1 . An emulsified composition for diluting a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof, comprising:
A) an ester of a fatty acid having 8 to 22 carbon atoms and an alcohol having 2 to 24 carbon atoms, the ester having a solidification point of not more than 10° C., at 50 to 90% by weight;
B) a nonionic surfactant consisting of a hydroxy fatty acid triglyceride adduct with 5 to 20 mol of ethylene oxide, at 0.5 to 20% by weight;
C) an emulsifier that is a partial ester of a polyhydric alcohol and a fatty acid, the partial ester being liquid at 40° C., at 0 to 20% by weight; and
D) water at 5 to 20% by weight.
2 . The emulsified composition for dilution of claim 1 , wherein the average particle diameter of the dispersion phase of the emulsified composition for dilution is 50 to 500 nm.
3 . A method of preparing a cancer vaccine composition, comprising diluting 0.25 to 1 part by volume of a water phase comprising a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof with 1 part by volume of the emulsified composition for dilution of claim 1 .
4 . The emulsified composition for dilution of claim 1 , wherein the fatty acid that constitutes ingredient A is oleic acid, myristic acid or 2-ethylhexanoic acid.
5 . The emulsified composition for dilution of claim 1 , wherein the ester of ingredient A is ethyl oleate, octyldodecyl myristate or cetyl 2-ethylhexanoate.
6 . The emulsified composition for dilution of claim 1 , wherein the hydroxy fatty acid triglyceride that constitutes the ingredient B nonionic surfactant is castor oil or hardened castor oil.
7 . A cancer vaccine composition comprising:
A) an ester of a fatty acid having 8 to 22 carbon atoms and an alcohol having 2 to 24 carbon atoms, the solidification point of the ester being not more than 10° C., at 30 to 80% by weight;
B) a nonionic surfactant consisting of a hydroxy fatty acid triglyceride adduct with 5 to 20 mol of ethylene oxide, at 0.5 to 20% by weight;
C) an emulsifier that is a partial ester of a polyhydric alcohol and a fatty acid, the partial ester being liquid at 40° C., at 0 to 20% by weight; and
E) a water phase comprising a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof, at 10 to 60% by weight;
wherein the composition is a W/O emulsion.
8 . The cancer vaccine composition of claim 7 , comprising ingredient A at 40 to 60% by weight;
ingredient B at 1.0 to 5.0% by weight;
ingredient C at 5.0 to 10.0% by weight; and
ingredient E at 30 to 50% by weight.
9 . A specific cytotoxic T cell inducer comprising:
A) an ester of a fatty acid having 8 to 22 carbon atoms and an alcohol having 2 to 24 carbon atoms, the solidification point of the ester being not more than 10° C., at 30 to 80% by weight;
B) a nonionic surfactant consisting of a hydroxy fatty acid triglyceride with 5 to 20 mol of ethylene oxide added thereto, at 0.5 to 20% by weight;
C) an emulsifier that is a partial ester of a polyhydric alcohol and a fatty acid, the partial ester being liquid at 40° C., at 0 to 20% by weight; and
E) a water phase comprising a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof, at 10 to 60% by weight;
wherein the composition is a W/O emulsion.
10 . The specific cytotoxic T cell inducer of claim 9 , comprising ingredient A at 40 to 60% by weight;
ingredient B at 1.0 to 5.0% by weight;
ingredient C at 5.0 to 10.0% by weight; and
ingredient E at 30 to 50% by weight.
11 . A kit for freshly preparing a cancer vaccine composition or specific CTL inducer, comprising a water phase comprising a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof, and the emulsified composition for dilution for diluting the water phase, of claim 1 .
12 . A method of preparing a cancer vaccine composition, comprising diluting 0.25 to 1 part by volume of a water phase comprising a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof with 1 part by volume of the emulsified composition for dilution of claim 2 .